Bernzott Capital Advisors Invests $4.49 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Bernzott Capital Advisors purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 93,985 shares of the biopharmaceutical company’s stock, valued at approximately $4,493,000. Halozyme Therapeutics accounts for about 2.2% of Bernzott Capital Advisors’ investment portfolio, making the stock its 28th biggest position.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. DekaBank Deutsche Girozentrale grew its holdings in Halozyme Therapeutics by 4.6% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 57,453 shares of the biopharmaceutical company’s stock worth $2,963,000 after buying an additional 2,546 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in Halozyme Therapeutics by 4.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 229,620 shares of the biopharmaceutical company’s stock worth $12,023,000 after buying an additional 10,651 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Halozyme Therapeutics by 12.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after buying an additional 209,530 shares in the last quarter. Mutual of America Capital Management LLC grew its holdings in Halozyme Therapeutics by 31.1% in the 2nd quarter. Mutual of America Capital Management LLC now owns 183,941 shares of the biopharmaceutical company’s stock worth $9,631,000 after buying an additional 43,614 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new position in Halozyme Therapeutics in the 2nd quarter worth approximately $182,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HALO has been the subject of a number of recent analyst reports. Wells Fargo & Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday. JMP Securities increased their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Piper Sandler increased their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. HC Wainwright increased their price target on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Finally, JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $55.37 on Friday. The firm has a market cap of $7.04 billion, a P/E ratio of 18.33, a PEG ratio of 0.40 and a beta of 1.24. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The stock has a fifty day moving average price of $49.75 and a two-hundred day moving average price of $54.07. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.